Zoetis Inc. (NYSE:ZTS) Stock Holdings Lowered by abrdn plc

abrdn plc decreased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,105,420 shares of the company's stock after selling 52,055 shares during the quarter. abrdn plc owned about 0.25% of Zoetis worth $179,084,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Algert Global LLC lifted its holdings in Zoetis by 29.5% during the second quarter. Algert Global LLC now owns 1,924 shares of the company's stock valued at $334,000 after purchasing an additional 438 shares in the last quarter. Quarry LP lifted its stake in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after buying an additional 153 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Zoetis by 57.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 13,977 shares of the company's stock worth $2,423,000 after buying an additional 5,073 shares in the last quarter. AMF Tjanstepension AB lifted its stake in shares of Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company's stock worth $20,594,000 after buying an additional 20,001 shares in the last quarter. Finally, Czech National Bank lifted its stake in shares of Zoetis by 6.1% in the third quarter. Czech National Bank now owns 92,291 shares of the company's stock worth $18,032,000 after buying an additional 5,339 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Up 0.2 %

NYSE:ZTS traded up $0.30 during mid-day trading on Tuesday, hitting $172.24. The company had a trading volume of 2,696,175 shares, compared to its average volume of 2,685,644. The firm has a market cap of $77.71 billion, a P/E ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business's fifty day moving average is $169.48 and its two-hundred day moving average is $179.39. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.36 EPS. As a group, research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis's dividend payout ratio is 37.59%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ZTS shares. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 price objective for the company. Morgan Stanley cut their price objective on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. Stifel Nicolaus dropped their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.